# Ligand Pharmaceuticals Inc.

**LGND**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000886163

**C**

**middle fifth of 369 graded peers in healthcare**

rank 161 of 369; percentile 43.5; sampling error 2.5 points; lower is stronger

A B C D E

**C, the tortoise**



## Scoreboard


| | |
|---|---|
| **Profitability** | E<br>percentile 89.4 |
| **Solvency** | A<br>percentile 9.3 |
| **Growth and financing** | B/C<br>percentile 39.6 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $1.6B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: dilution, distress |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 27, 2026<br>251 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026 |
| **Last close** | $316.10<br>2026-11-04; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 27, 2026*

We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure. Capital deployment and technology licensing are the primary drivers of our long-term growth.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 89.4** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *required facts have no common fiscal period end* | | | | | | |
| Accruals ratio | 6.0% | (6.6%) | | 89.4 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 1* | | | | | | |
| **Solvency, sleeve percentile 9.3** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |
| Altman Z double-prime | 6.75 | (0.35) | | 15.0 | 746 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *latest aligned inputs end 2012-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 22.23x | 2.92x | | 3.6 | 827 | 2025-12-31 |
| **Growth and financing, sleeve percentile 39.6** | | | | | | |
| Revenue growth, three-year compound | 11.0% | 10.1% | | 47.7 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | (25.8%) | 10.9% | | 92.6 | 96 | 2025-12-31 |
| Reinvestment rate | 1,454.9% | 37.1% | | 1.0 | 104 | 2025-12-31 |
| Asset growth, three years | 27.0% | 2.2% | | 17.1 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 156 | Myomo, Inc. (MYO) | 42.1 | B/C | fortress balance sheet |
| 157 | Community Health Systems Inc. (CYH) | 42.4 | B/C | |
| 158 | Nephros Inc. (NEPH) | 42.7 | C | fortress balance sheet |
| 159 | Sight Sciences, Inc. (SGHT) | 42.9 | C | fortress balance sheet |
| 160 | Immucell Corp. (ICCC) | 43.2 | C | |
| 161 | Ligand Pharmaceuticals Inc. (LGND) | 43.5 | C | |
| 162 | Davita Inc. (DVA) | 43.8 | C | |
| 163 | Addus HomeCare Corp. (ADUS) | 44.0 | C | |
| 164 | NovoCure Ltd. (NVCR) | 44.3 | C | fortress balance sheet |
| 165 | Repligen Corp. (RGEN) | 44.6 | C | late filer, fortress balance sheet |
| 166 | Avita Medical, Inc. (RCEL) | 44.8 | C | short runway |

## What the price implies

*at the 2026-11-04 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 63.3% | (2.2%) | 82 |
| Distance from 52-week high | (2.1%) | (26.8%) | 84 |
| EBIT to enterprise value | not computable | (1.4%) | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Free cash flow yield | not computable | (0.9%) | |
| Book value to price | not computable | 0.27 | |
| Sales to price | not computable | 0.28 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | 0.32 | (0.19) | 82 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $56.0M |
| Operating cash flow, four quarters | $91.0M |
| Months of runway | not finite |
| Days since last periodic filing | 6 (10-Q received Oct 30, 2026) |
| Median daily dollar volume, 63 sessions | $62.5M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $251.5M | 2018-12-31 | 2021-02-24 | 10-K | 21-000050 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $6.3M | 2018-12-31 | 2019-02-28 | 10-K | 19-000041 |
| 3 | assets | us-gaap:Assets | $1.3B | 2018-12-31 | 2020-02-27 | 10-K | 20-000025 |
| 4 | net income | us-gaap:NetIncomeLoss | $124.5M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $49.4M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 6 | assets | us-gaap:Assets | $1.6B | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 7 | assets | us-gaap:Assets | $941.8M | 2024-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 8 | current assets | us-gaap:AssetsCurrent | $832.3M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $37.4M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $608.1M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | $41.0M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 12 | book equity | us-gaap:StockholdersEquity | $1.0B | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 13 | liabilities | us-gaap:Liabilities | $543.4M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 14 | total debt | us-gaap:LongTermDebt | $27.5M | 2012-12-31 | 2013-03-14 | 10-K | 13-000025 |
| 15 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $12.4M | 2012-12-31 | 2016-11-14 | 10-K | 16-000239 |
| 16 | operating income | us-gaap:OperatingIncomeLoss | $193,000 | 2012-12-31 | 2015-02-23 | 10-K | 15-000028 |
| 17 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $2.7M | 2012-12-31 | 2015-02-23 | 10-K | 15-000028 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | $11.9M | 2023-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 19 | interest expense | us-gaap:InterestExpense | $656,000 | 2023-12-31 | 2024-02-29 | 10-K | 24-000009 |
| 20 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $268.1M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $167.1M | 2024-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 22 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $131.3M | 2023-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $196.2M | 2022-12-31 | 2025-02-28 | 10-K | 25-000012 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $452,000 | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $97.0M | 2024-12-31 | 2026-02-27 | 10-K | 26-000006 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.8M | 2024-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $49.6M | 2023-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.5M | 2023-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $137.8M | 2022-12-31 | 2025-02-28 | 10-K | 25-000012 |
| 30 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $17.9M | 2022-12-31 | 2025-02-28 | 10-K | 25-000012 |
| 31 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $33.8M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 32 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $159.0M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 33 | income tax | us-gaap:IncomeTaxExpenseBenefit | $34.5M | 2025-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 34 | current assets | us-gaap:AssetsCurrent | $331.6M | 2024-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 35 | current liabilities | us-gaap:LiabilitiesCurrent | $37.1M | 2024-12-31 | 2026-02-27 | 10-K | 26-000006 |
| 36 | assets | us-gaap:Assets | $787.2M | 2023-12-31 | 2025-02-28 | 10-K | 25-000012 |
| 37 | assets | us-gaap:Assets | $762.7M | 2022-12-31 | 2024-02-29 | 10-K | 24-000009 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.